From experiments with purified proteins, it has been concluded that factor Xla (FXla) is inhibited in plasma mainly by a,-antitrypsin (alAT), followed by antithrombin 111 (ATIll), Cl-inhibitor (Cllnh), and a2-antiplasmin (a2AP). However, the validity of this concept has never been studied in plasma. We established the relative contribution of different inhibitors to the inactivation of FXla in human plasma, using enzyme-linked immunosorbent assays (ELISAS) for the quantification of complexes of FXla with alAT, Cllnh, a2AP. and ATIII. We found that 47% of FXla added to plasma formed complexes with Cllnh, 24.5% with a2AP, 23.5% with alAT, and 5% with ATIII. 33 kD) , the latter each containing one active plasma proteinase-inhibitors.6.L6 The activity of FXIa is regulated in plasma by protease inhibitors, which include a,-antitrypsin (a1 AT)," antithrombin I11 (ATIII)," Cl-inhibitor (ClInh)," ayantiplasmin (a2AP);' and protein C inhibitor." All these proteins belong to the superfamily of serine protease inhibitors. In addition, platelets may regulate the activity of FXIa via the release of two different inhibitor^.^^-*^ However, the precise role of these platelet inhibitors is unclear.' It is believed that alAT is the main inhibitor of FXIa, followed by ATUI, ClInh, and a2AP.Z5 However, these conclusions are mainly derived from experiments in purified systems and may not necessarily be relevant for inactivation of FXIa in the plasma milieu. Earlier reports have shown the usefulness of assays measuring enzyme-inhibitor complexes to monitor activation and inactivation of enzymes in pla~ma.'~-~' In the present study, we have developed specific, sensitive, and reproducible enzyme-linked immunosorbent assays (ELISAs) to quantitate complexes between FXIa and ClInh, a1 AT, a2AP, or ATIII, respectively. These assays were used to investigate the contribution of the respective inhibitors to inactivation of FXIa in plasma. In addition, the influence on FXIa inactivation inhibitors in plasma was independent of whether FXla was added to plasma, or was activated endogenously by kaolin, celite, or glass. However, in the presence of heparin (1 or 50 U/mL), Cllnh appeared to be the major inhibitor of FXla, followed by ATIII. Furthermore, at lower temperatures, less FXla-Cllnh and FXla-alAT complexes but more FXla-a2AP complexes were formed. These data demonstrate that the contribution of the different inhibitors to inactivation of FXla in plasma may vary, but Cllnh is the principal inhibitor under most conditions.
HK serves as a nonenzymatic cofactor in these reactions. However, the physiologic role of the contact system in activating FXI is uncertain,' and recent studiess3' suggest alternative pathways to activate FXI. FXI in plasma is complexed to HK" and present at a concentration of 3 to 6 pgl m L . 5 * " " 3 It is a dimeric glycoprotein and consists of two identical polypeptide chains [mass ratio (Mr) of 80 kD] that are held together by a disulfide bond. Upon activation, each polypeptide chain can be cleaved at an internal peptide bond, giving rise to disulfide-linked heavy and light chains. FXIa is thus composed of two heavy chains (Mr, 50 kD) and two light chains (Mr, 33 kD), the latter each containing one active plasma proteinase-inhibitors.6.L6 The activity of FXIa is regulated in plasma by protease inhibitors, which include a,-antitrypsin (a1 AT)," antithrombin I11 (ATIII)," Cl-inhibitor (ClInh)," ayantiplasmin (a2AP);' and protein C inhibitor." All these proteins belong to the superfamily of serine protease inhibitors. In addition, platelets may regulate the activity of FXIa via the release of two different inhibitor^.^^-*^ However, the precise role of these platelet inhibitors is unclear.' It is believed that alAT is the main inhibitor of FXIa, followed by ATUI, ClInh, and a2AP.Z5 However, these conclusions are mainly derived from experiments in purified systems and may not necessarily be relevant for inactivation of FXIa in the plasma milieu.
Earlier reports have shown the usefulness of assays measuring enzyme-inhibitor complexes to monitor activation and inactivation of enzymes in pla~ma.'~-~' In the present study, we have developed specific, sensitive, and reproducible enzyme-linked immunosorbent assays (ELISAs) to quantitate complexes between FXIa and ClInh, a1 AT, a2AP, or ATIII, respectively. These assays were used to investigate the contribution of the respective inhibitors to inactivation of FXIa in plasma. In addition, the influence on FXIa inactivation als with congenital deficiencies of FXI, factor XII, prekallikrein, or HK were purchased from George King Biomedical (Overland Park, KS).
Purified human FXI was obtained from Kordia Laboratory Supplies (Leiden, The Netherlands) and was stored at -70°C in 4 mmoU L acetate, 150 m o l & NaCl, pH 5.3. FXI was a single band on nonreducing and reducing sodium dodecyl sulfate (SDS)/IO% (wt/ vol) polyacrylamide gel electrophoresis (PAGE; Kordia Laboratory Supplies). @-factor XIIa was prepared from purified human factor XII, as described." All protease inhibitors were of human origin. ClInh was obtained from Behringwerke AG (Marburg, Germany); alAT, a2AP, and ATIII were from Calbiochem (La Jolla, CA).
Preparation of FXIa. FXIa was prepared by incubating FXI (100 nmol/L, final concentration) with p-factor XIIa (100 nmol/L, final concentration) at 37°C in 100 mmol/L Tris-HCI, 140 mmoVL NaC1, 0.1% (wtlvol) Tw, pH 7.4. The activation was monitored by the appearance of FXIa amidolytic activity. When no further increase in the amidolytic activity was observed, the reaction was stopped by neutralizing p-factor XIIa with a fivefold molar excess of monoclonal antibody (MoAb) OT-2, which completely inhibits the amidolytic activity of P-factor XIIa (see below). Amidolytic activity of FXIa was measured by using the chromogenic substrate S-2366 (0.4 mmol/L) in a buffer containing 100 mmol/L. Tris-HCI, 150 mmoU L NaCI, 0.1% (wt/vol) Tw at pH 8.0. The FXIa preparation obtained expressed no amidolytic activity against S-2302 when tested at a similar concentration as was used for S-2366 amidolytic activity measurement, indicating that the FXIa preparation contained little, if any, (pre)kallikrein.
MoAbs. MoAb XI-5 was obtained after fusion of spleen cells from mice immunized with human FXI with Sp2/0-Ag14 myeloma cells, according to a procedure described b e f~r e .~" Culture supernatants were screened using a radioimmunoassay procedure in which goat-antimouse immunoglobulin antibodies coupled with Sepharose beads were used in combination with Iz5I-FXI. Positive clones were subcloned by limiting dilution. MoAb XI-5 appeared to be directed against the heavy chain of FXIa on immunoblotting and has been used for affinity chromatography of FXI? MoAb RI1 binds equally well to native, complexed, and inactive C11nh.33 MoAb AT-l5 is directed against complexed and inactivated alAT34; and MoAb AAT-111-0, against ATIII. MoAb AAP-11 recognizes inactivated and complexed a2AP.3r MoAb OT-2 is directed against the light chain of activated factor XI1 and blocks its catalytic activity." All MoAbs were purified from mouse ascites fluid by affinity chromatography on protein-A Sepharose (Pharmacia. Uppsala, Sweden). Biotinylation of antibodies using LC-biotin-N-hydroxysuccinimide ester (Pierce, Rockford, IL) was performed according to the manufacturer's instructions.
ELISAs for FXIa-FXIa inhibifor complexes. Similar ELISA procedures were developed to detect the different FXIa-FXIa inhibitor complexes. The wells of microtiter plates (Dynatech, Plochingen, Germany) were incubated for 2 hours at room temperature (or overnight at 4°C) with MoAb XI-5 ( I O 0 pL per well; 3 pg/mL. in 0.12 molL H,B03, 0.12 m o w KCI, 0.08 molL NaOH, pH 9.5). The plates were washed with phosphate-buffered saline (PBS; 10 mmoV L sodium phosphate, 140 mmoW NaCl, pH 7.4) containing Tw 0.02% (wt/voI) after each of the following incubation steps, which were all performed with 100 pL per well at room temperature. The wells were blocked for 30 minutes with either 3% (wt/vol) bovine serum albumin in PBS (ELISAs for FXIa-a2AP and FXIa-ATIII complexes), or with 2% (voUvol) milk in PBS (ELISA for FXIaClInh complexes), or with PBS containing 0.1% (wt/vol) Tw and 0.2% (wtlvol) gelatine (PTG; ELISA for FXIa-alAT complexes). The wells were then incubated for 1 hour with aliquots of test samples and standards diluted in PTG containing 1% (volhol) normal mouse serum (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands) or in PBSmilk 2% (ELISA for FXIa-ClInh complexes). Serial dilutions of kaolin-activated pooled normal human EDTA-plasma were used as standards. Then the microtiter plates were incubated for I hour with the respective biotinylated MoAb diluted in PTG-l% mouse serum. In the next step, FXIa-inhibitor complexes were detected by incubating the plates for 30 minutes with polymerized horseradish peroxidase bound to streptavidin (Janssen Chimica) I to 10,000 diluted in PBS-milk 2%, or horseradish peroxidase-labeled streptavidin (Amersham International plc, Amersham, UK) l to 1,000 diluted in PTG (ELISA for FXIa-alAT complexes). Bound peroxidase was visualized by incubating the wells with 0.1 1 molL sodium acetate, pH 5.5, containing 0.1 mg/mL 3,3',5,5'-tetramethylbenzidin (Merck, Darmstadt, Germany) and 0.003% (voUvol) H,O,. Reaction was stopped with 2 mom sulfuric acid, and absorbance was read at 450 nm on a Multiskan plate reader (Labsystems, Helsinki, Finland).
Quantijicntion of FXIu-FXln inhibitor complexes. FXla-FXIa inhibitor complexes were prepared by incubating FXIa (27 nmol/L or 45 nmolk, final concentration) with the respective inhibitors ( 1 to 3 pnoUL, final concentrations) for 3 hours at 37°C. Heparin (final concentration, 2 UlmL) was added to the incubation mixtures containing ATIII. None of the complex mixtures showed amidolytic activity against S-2366. For the quantification of the complexes, it was, therefore, assumed that in these mixtures FXIa was completely bound to the respective protease inhibitors. The amount of the complexes in the mixtures was estimated to be equal to the initial molar FXIa Concentration. Throughout this report, molar concentrations of FXIa and FXIa-inhibitor complexes were expressed based on an Mr of FXla of 80 kD, thus calculating the active sites of FXIa. The mixtures were then preincubated for 30 to 60 minutes either in fresh plasma or in buffer and thereafter measured in the respective FXIaFXIa inhibitor ELISAs and compared with the kaolin-activated reference plasma. This approach allowed calculation of the different FXIa-FXIa inhibitor complexes in this reference plasma.
In vitro activation of the contact system in plasma. One volume of pooled EDTA-plasma, of EDTA-plasma from individual donors, of hirudin-plasma, or of contact factor-deficient plasmas was mixed at 37°C with 1 v01 of PBS containing various amounts of either kaolin or celite (and 300 U/mL hirudin in the case of hirudinplasma). After an incubation time of 30 minutes, activation was stopped by adding 3 v01 of PBS containing 0.1 mg/mL SBTI and 0.05% (wtlvol) Polybrene (stop solution). In some experiments, stop solution without Polybrene was used. Kaolin or celite were removed by centrifuging reaction mixtures for 5 minutes at I3,OOOg. Kaolinactivated standard plasma was prepared similarly, by activating pooled normal EDTA-plasma for 30 minutes with kaolin in PBS (5 mg/mL, final concentration). Analogous activation of EDTA-plasma with kaolin was performed in the presence of heparin at final concentrations of I or 50 U/mL (heparin-plasma). For glass activation, EDTA-plasma was diluted 1:l with PBS and incubated for I hour at 37°C in glass tubes. Reaction was stopped as described above.
Inactivation of exogenous FXIa ndded to plasma. FXla was added to EDTA-plasma, to fresh plasma containing Polybrene (0.05%, wt/vol), to hirudin-plasma (mixed with an equal volume of hirudin to a final concentration of 150 U/mL), to EDTA-plasma containing heparin (1 or 50 U/mL), to FXI-deficient plasma, or to HK-deficient plasma (final concentration of FXIa ranging between 1.35 and 22.5 nmol/L). After an incubation period of 1 hour at 37°C. or after various time intervals, dilutions of the mixtures were tested in the ELISAs for the different FXIa-FXIa inhibitor complexes. The EDTA-plasma and hirudin-plasma used in these experiments contained 5% (vol/vol) of MoAh OT-2 (0.64 tng/mL), which blocks the catalytic activity of FXIIa to prevent endogenous contact activation during the incubation period. Control experiments showed no generation of FXIa-FXIa inhibitor complexes in the absence of exog- 
RESULTS

ELISAs for FXIa-FXIa inhibitor complexes.
In initial experiments, optimal conditions for the ELISAs to detect FXIaFXIa inhibitor complexes were established (see Materials and Methods). Clear dose response curves were obtained when kaolin-activated reference plasma was tested, whereas background absorbance values were observed with dilutions of unactivated fresh plasma (Fig 1) . The specificity of the ELISAs was initially established in experiments with purified protease-protease inhibitor complexes. Dilutions of these complexes were tested in each ELISA and compared with dose response curves of the kaolin-activated reference plasma. In all instances, the mixtures of FXIa and a given protease inhibitor yielded a maximal response only in the appropriate assay (Table 1) . Furthermore, dilutions of FXIa, ClInh, a1 AT, a2AP, or ATIII alone yielded no significant response in the assays, and purified thrombin-AT111 complexes (TAT complexes) up to a concentration of 625 pg/L showed an absorbance in the range of background. In addition, comparison of the parallel dose response curves of the prepared FXIa-FXIa inhibitor complexes of known concentrations with those obtained with kaolin-activated plasma enabled us to determine the concentration of the various complexes present in the latter reference plasma (Fig 1) . From five separate experiments, it was calculated that kaolinactivated reference plasma contained (mean ? SD) 13. ELISAs, plasmas deficient in FXI, factor XII, prekallikrein, or HK were activated with kaolin and tested for FXIa-FXIa inhibitor complexes. As shown in Table 2 , generation of enzyme-inhibitor complexes was observed in prekallikreindeficient plasma, confirming that contact activation can occur in the absence of prekallikrein via autoactivation of factor plasmas did not result in detectable amounts of FXIa-FXIa inhibitor complexes. The epitope recognized by the capture antibody MoAb XI-5 is located on the heavy chain region of FXI. Thus, binding of a certain FXIa-FXIa inhibitor complex to this antibody should not be dependent on the nature of the serpin complexed to the light chain of FXIa. Even a different capturing of the various FXIa-FXIa inhibitor complexes would not have influenced the results, as this phenomenon would occur with both the kaolin-activated reference plasma and the purified complexes used for calibration of this plasma. However, capturing of a given complex could be influenced by the presence (of high amounts) of other FXIa-FXIa inhibitor complexes, eg, by displacing complexes with lower affinity. To investigate this point, FXIa-FXIa inhibitor complexes were prepared and measured in the respective ELISAs either in the absence or in the presence of equal amounts of the other complexes (34.5 nmol/L total concentration). The values obtained in the absence/presence of other FXIa-FXIa inhibitor complexes were (mean of two experiments) 8.51 8.4 nmol/L,7/6.9 nmoVL, 9.718.8 nmoVL, and 9.3B.6 nmoV L for FXIa-ClInh, FXIa-alAT, FXIa-a2AP, and FXIa-ATIII, respectively, showing no influence on measurement of a given complex by the presence of other FXIa-FXIa inhibitor complexes. In addition, these results confirm the specificity of the ELISAs for the respective DCIa-FXIa inhibitor complexes.
The anti-FXI MoAb coated to the microtiter plate binds native as well as complexed FXI. It was thus essential to XII.32.37 However, kaolin incubation of the other deficient establish that free FXI in normal plasma would not compete with FXIa-protease inhibitor complexes for binding to the limited amount of the capture antibody. This was studied by adding increasing amounts of normal plasma to each sample of the standard curve (kaolin-activated plasma). No decrease of the absorbance value up to a concentration of normal plasma of 20% (vol1vol) in the assays was observed (data not shown). Furthermore, addition of fresh plasma to preformed complexes also did not influence the response in the ELISAs (Fig 1) . However, higher concentrations of normal plasma resulted in a diminished absorbance and, thus, decreased sensitivity. Therefore, samples were at least diluted fivefold in the ELISAs. Taking into account this at least fivefold dilution of the test samples, the lower detection limits of the assays were calculated from seven separate experiments as the values of a fivefold diluted sample with an absorbance twice that of background ( Table 3 ). The mean values (?SD) for the intraassay coefficient of variation (CV) and the interassay CV were calculated from six measurements of the standard samples and from five assays of four test samples, respectively, and are shown for each ELISA in Table 3 .
Formation of FXIa-FXIa inhibitor complexes after in vitro contact activation of plasma. One volume of pooled EDTA-plasma, of hirudin-plasma, or of EDTA-plasma from individual donors was incubated at 37°C with 1 v01 of PBS containing different amounts of either kaolin or celite, or was incubated in glass tubes. FXIa-FXIa inhibitor complexes in the mixtures were measured, and the relative distribution of FXIa between the four different inhibitors was calculated using the sum of the concentrations of FXIa-ClInh, FXIaalAT, FXIa-a2AP, and FXIa-ATIII complexes as 100%. After activation of plasma with kaolin, 30% ? 5.1% of the FXIa-inhibitor complexes generated were FXIa-C IInh; 33.4% ? 2.6%, FXIa-a1AT; 31.4% 2 3.0%, FXIa-a2AP; and 5.2% ? 0.8%, FXIa-ATIII complexes. This distribution was not dependent on the concentration of kaolin and was the same for celite-or glass-activation (Fig 2) . Similar distribution patterns were observed in hirudin-plasma (Fig 2) and in individual plasma samples (data not shown). Incubation of kaolin with fresh plasma containing Polybrene 0.05% (wt/ vol) did not result in measurable amounts of FXIa-FXIa inhibitor complexes, thus confirming that this cationic detergent prevents contact activation of plasma. However, Polybrene was important to fully recover generated FXIa-FXIa inhibitor complexes from the activating surface: the total After incubation with kaolin (5 mg/mL), plasmas congenitally deficient in one of the indicated contact system proteins were tested for the presence of the various FXla-FXla inhibitor complexes. Results are expressed as nanomolars. Kaolin activation of EDTA-plasma containing I or S0 U/ mL heparin was performed as described above. The total amount of generated FXIa-inhibitor complexes was between 44.1 t-1 .S nmol/L and 59.4 t 6.8 nmol/L, respectively, and thus, approximately the same as in plasma without heparin. However, the presence of heparin resulted in a completely different distribution of FXIa between its inhibitors (Fig 3) : FXla-ATIII complexes now accounted for 29.8% t-3.1% to 345% t 0.6%. FXla-CIInh complexes had increased, too, and constituted 43.3% t O S % to 6S.8% t-3.8% of the FXIa-FXla inhibitor complexes. whereas complexes of FXla with al AT and a2AP were reduced, particularly at the higher heparin concentration. Inactivation of e,wCqenorrs FXIa in plasma. FXIa was added to EDTA-plasma (containing MoAb OT-2 at concentrations sufficient to prevent activation of the endogenous contact proteins during incubation time). to fresh plasma (containing Polybrene to avoid in vitro contact activation). or to hirudin-plasma (containing MoAb OT-2) to yield final concentrations of 1.35 to 22.5 nmol/L. After incubation at 37°C for 60 minutes. FXla-FXIa inhibitor complexes were measured. The distribution of FXla between its inhibitors in fresh plasma (Fig 4) was essentially the same as observed after kaolin-. celite-, or glass-activation of normal plasma (Fig 2) , with 31.2% t 3.5% of the formed complexes being FXla-CIInh complexes, 3 I .9% t-2.7% FXla-al AT complexes, 30.8% t 2.0% FXla-a2AP complexes, and 6.1 % t-1.0% FXla-ATIII complexes. However, when FXIa was incubated in EDTA-plasma (or hirudin-plasma) in the absence of Polybrene, the relative amount of FXla-C 1 Inh complexes increased to 47% 5 2.4% (49.5% t 1.3%). whereas FXIa-al AT, FXla-a2AP and FXIa-ATIII complexes decreased to 23.5% ? 2.1% (22% ? 0.8%). 24.5% +-2.5% (24% t-1.6%), and 5% (4.5% t-0.6%). respectively. The distribution pattern of exogenous FXla between the four inhibitors was independent of its final concentration. Moreover. the relative amounts of formed FXla-FXIa inhibitor complexes were in the same range when FXIa was added to congenitally FXI-deficient plasma (data not shown). No FXla-FXla inhibitor complexes were generated in the absence of added FXla.
The total amount of formed FXIa-FXla inhibitor complexes increased during incubation time and reached a maximum at 60 minutes (Fig S) . The relative amounts of FXla complexed to AT111 and a2AP were similar for all incubation times, ranging from 4% to 6% and from 24.6% to 30.4%. respectively, whereas the contribution of C1 Inh to inactivation of FXIa decreased from 60.7% after I minute of incubation to 46% after 120 minutes, and the contribution of a1 AT increased from 10.7% to 22.3%, respectively.
Effect of heparin and HK on the distribution of exogenous FXla between its inhibitors. Considering the well-known effect of heparin on the functional activity of ATIII, and recent data that the presence of HK favors inhibition of kallikrein by ATIlI,38 we decided to investigate the influence of heparin and HK on the inactivation pattern of exogenously added FXIa. Therefore, FXIa (22.5 nmol/L, final concentration) was added to EDTNOT-2-plasma containing 1 or SO U/mL heparin (heparin-plasma), or to HK-deficient plasma, containing 0 or 1 U/mL heparin. As shown in Fig 6, inclusion of heparin dramatically changed the distribution of FXIa between its inhibitors: the amount of FXIa complexed to ATIII had increased to 42% 2 1.6% ( 1 U/mL heparin) and to 3 I % ? 3.6% ( S O U/mL heparin) of total FXla complexes, and FXIa-C1 Inh complexes increased to S 1.3% ? 1 .S% and 67% ? 3.6%, respectively, whereas FXla-al AT and FXIaa2AP complexes were strongly reduced. Similar results were obtained using FXIa at a final concentration of 3.6 nmol/L. Again, no generation of FXla-FXIa inhibitor complexes was observed in the absence of exogenous FXIa.
FXIa added to HK-deficient plasma resulted in approximately the same distribution of FXla-inhibitor complexes as found in EDTA-plasma (Fig 6) . When heparin was added to HK-deficient plasma, again FXIa-ATIII complexes remarkably increased, and FXla-alAT and FXIa-a2AP complexes decreased, but in a less-pronounced manner than observed in EDTA-plasma. Complexes of FXla and ClInh were not affected by the addition of heparin to HK-deficient plasma.
Effect of temperature on FXIa-FXla inhibitor complex formation. Figure 7 shows the results obtained from experiments in which FXla (22.5 nmol/L, final concentration) was added to EDTA-plasma (containing MoAb OT-2) and incubation was performed at 37"C, 20°C, or 4°C for 1 hour, 2 hours, and 4 hours, respectively. The total amount of FXIa recovered in the FXla-inhibitor complexes after the respective incubation times was (mean ? SD of four separate experiments) 14. to ClInh decreased from 47% -t 2.4% to 22.8% -C 2.2% at lower temperature, whereas the amount of FXIa-a2AP increased from 24.5% It-2.5% to 55.5% -C 1.0%. Changes in the other complexes were less pronounced, with FXIaalAT complexes slightly decreased and FXIa-ATIII complexes increased with lower incubation temperature.
DISCUSSION
It is generally a g~-e e d~,~ that in the absence of heparin, alAT accounts for 65% to 70% of the FXIa inhibitory activity of human plasma, whereas others inhibitors are considered to be less important. However, it was emphasized39 that these conclusions are based mainly on experiments with purified proteins and, therefore, may be of little relevance in determining the physiologic inhibitors of activated FXI.
Analysis of the formation of complexes between FXIa and its possible inhibitors in plasma may better reflect the inactivation of FXIa in plasma. However, no extensive studies in plasma were performed until now, and methods to measure these complexes were only partially available.@ Therefore, we developed immunoassays for the detection of complexes of FXIa and a1 AT, ClInh, a2AP, or ATIII, respectively.
Using these assays, we present evidence that ClInh is not only the predominant inhibitor of factor XIIa4' and kallikrein,42 but also the main inhibitor of FXIa, contributing 47% to FXIa inactivation in EDTA-plasma, followed by a2AP (24.5%), alAT (23.5%), and ATIII (5%). The same results were obtained using plasma containing hirudin instead of EDTA (which affects the concentration of divalent cations), thereby suggesting that the pattern of FXIa inactivation found may also represent the in vivo situation.
The ELISAs detailed in the present study proved to be specific, reproducible, and sensitive, detecting 9 to 41 pmoY L complexed FXIa (considering the dilution of plasma samples to be tested), which corresponds to activation of about 0. l % of plasma FXI. The sum of the FXIa active sites present in the different complexes in kaolin-activated reference plasma was found to be 44.9 nmol/L, corresponding to 3.6 pg/mL of FXI. This is in the range of the amount of FXI present in normal plasma (about 3 to 6 pg/mL5*""3), assuming that each active site of both 80 kD subunits of FXIa can be inactivated by proteinase inhibitors. Indeed, experiments performed using an ELISA system based on MoAb RI1 (against ClInh) coated to the microtiter plate and MoAb AT-l5 (against complexed alAT) as detection antibody showed that FXIa was complexed with two different inhibitors, probably each binding to one of the two light chains (data not shown). Thus, FXIa complexed to two different inhibitors will be detected in two different ELISAs. This is in agreement with reports that each of both active sites in FXIa can be inactivated by one inhibitor.6*I6
Inactivation of FXIa generated during contact activation by kaolin, celite, or glass in EDTA-plasma was essentially the same as that observed with exogenous FXIa added to Polybrene-containing plasma. Although the amount of FXIaFXIa inhibitor complexes generated in these experiments was dependent on the concentrations of the respective contact activating surfaces, the relative distribution of FXIa between the four inhibitors did not change. Factor XIIa is protected against inactivation by ClInh when bound to glass,36 ~ulfatides,''~ or k a~l i n .~~.~~ FXIa bound to celite has also been reported to be protected from inactivation by ClInh and a2AP.20 Therefore, it seems likely that in the experiments with Polybrene in the stop buffer, FXIa was dissociated from the activators as active FXIa and became subsequently complexed with its inhibitors in the presence of Polybrene, which, as was obvious from the experiments with exogenously added FXIa, may have influenced the distribution slightly. However, addition of Polybrene to stop the reaction was necessary to fully remove FXIa from the activating surface, in agreement with an earlier report suggesting that FXI remains surface-bound after activation." Thus, our results indicate that endogenously generated or exogenously added FXIa is inactivated in plasma in a similar way. This is in contrast with the inactivation of plasma kallikrein: the ratio of kallikrein complexed with a,-macroglobulin or ClInh has been reported to be dependent on whether this enzyme was generated endogenously or added to plasma.29
In the presence of heparin, FXIa was mainly inhibited by ClInh and ATIII. Using plasma containing 1 U/mL heparin (high therapeutic dose) or 50 U/mL heparin (suprapharmacologic levels of heparin), we found a six-to eightfold increase of the relative contribution of ATIII to inactivation of FXIa in plasma. This effect of heparin was observed with different FXIa concentrations (3.6 and 22.5 nmol/L) and was independent of whether FXIa was added exogenously or generated during kaolin activation of plasma (Figs 3 and 6) . These results correspond with those obtained using purified sys- Others, however, concluded that heparin has only a minor influence on the inactivation of FXIa by ATIII in plasma: Nishikado et a14" found no significant increase in FXIa-AT111 complexes in patients receiving up to 20,000 U/d of heparin, and Scott and Colman4' reported only a 1 .&fold potentiation of the inactivation rate of FXIa by plasma containing high therapeutic levels of heparin ( l U/mL). Nevertheless, our results unequivocally show that the relative contribution of ATIII to FXIa inactivation in plasma is strongly increased in the presence of heparin. Thus, together with a recent study showing that the inactivation of kallikrein by ATIII is potentiated by heparin,'x our study indicates that ATIII may be an important protein in the regulation of activated contact system enzymes.
Suprisingly, heparin also enhanced the formation of FXIaClInh complexes, whereas it diminished complexes of FXIa with alAT and a2AP, respectively. This may be explained either by accelerating the inhibition of FXIa by C 1 Inh or by suppressing the inactivation of FXIa by a1 AT and a2AP. Evidence that heparin potentiates C1 Inh has been reported."+'
The inhibitor spectrum was the same in HK-deficient plasma when compared with normal plasma (Fig 6) . Therefore, we concluded that HK had no effect on the distribution of FXIa between its inhibitors. After addition of heparin to HK-deficient plasma, the observed increase in FXIa-ATIII complexes was slightly less pronounced than that in normal heparin-plasma. This may indicate a small contribution, if at all, of HK to the heparin-dependent potentiation of the inactivation of FXIa by ATIII. This finding is in contrast with the remarkable contribution of HK to acceleration of the inactivation rate of plasma kallikrein by ATIII in the presence of heparin.'x Our results are somewhat in contrast with those obtained previously with purified protein systems, where it was concluded that alAT is the predominant inhibitor of FXIa in plasma." This may be due to several reasons. First, the second-order rate constant for the inhibition of FXIa by C 1 Inh, which was used to predict the relative importance of ClInh in the previous is three times less than was determined by others.5" Second, plasma components may influence the inhibitory capacity of the different inhibitors. We found in preliminary experiments that polyanions in plasma may change the distribution of FXIa between its inhibitors in favor of CIInh. This is in accordance with the observation in the present study that Polybrene (a polycation that neutralizes polyanions) diminishes the contribution of ClInh from 47% to 31%. The presence of polyanions in plasma was not considered in the previous study with purified protein^.'^ A discrepancy between results obtained from purified protein systems and from plasma system has also been found for the inhibition of plasmin by CIInh."
Apart from the four mentioned plasma protease inhibitors, other proteins were described as FXIa inhibitors. Protease nexin-2, a protein of the a-granules of platelets," was found to have inhibitory activity against FXIa?' which is accelerated by heparin. In addition, a low-molecular-weight platelet inhibitor of FXla called PIX1 was recently In preliminary experiments (data not shown). we investigated the influence of released (a-granule) contents of platelets to the distribution of FXIa between its plasma inhibitors. Platelet-rich plasma (PRP) was stimulated with Ca-ionophore in the same manner as described for purification of protease nexin-2.5' When FXIa was added to supernatant plasma of activated PRP, neither the total amount of FXIa-FXIa inhibitor complexes nor the distribution of FXIa between its inhibitors was different from unactivated supernatant or from EDTA-plasma. In addition, inclusion of heparin in supernatant plasma of activated PRP did not result in a different FXIa inactivation pattern compared with EDTA-plasma containing heparin. However, more detailed studies are necessary to clarify the role of platelets in inactivation of plasma FXIa.
Finally, we demonstrated that the distribution of FXla between its inhibitors was affected by the incubation temperature (Fig 7) . At lower temperature, the relative amount of FXIa bound to ClInh decreased, whereas FXIa-a2AP complexes increased. The decreased inhibitory capacity of C 1 Inh at lower temperature has been shown for the inactivation of both plasma kallikrein29 and activated factor XILS4
In summary, the present work indicates that (1) the contribution of protease inhibitors to inactivation of FXIa in plasma appears to be different than previously assumed based on kinetic analysis of purified proteins: C 1 Inh may be the predominant FXIa inhibitor; and (2) heparin alters the distribution of FXIa between its inhibitors. Further studies are required to determine the relative contribution of the different protease inhibitors in the neutralization of FXla in vivo. 
